mTOR and cancer: many loops in one pathway
Introduction
Adequate cellular levels of energy and nutrients are a prerequisite for successful cell growth and division. Therefore, cells have acquired mechanisms to sense energy and nutrients before committing to grow and divide. In all eukaryotes, the target of rapamycin (TOR) protein is a master regulator that integrates the signals from nutrient and energy sensors with cell growth and proliferation, so as to ensure that they are triggered only during favorable conditions. The mammalian TOR (mTOR) also integrates growth factor signaling together with nutrients and energy as a mechanism to coordinate cell growth and proliferation in large number of cells within different organs. In addition to this, a network of regulatory loops affects the function of mTOR and impact on therapeutic approaches aimed at targeting mTOR, which will be discussed here.
Section snippets
The mTOR signaling pathway
mTOR forms two different protein complexes defined by the proteins to which it is bound, exerting different but related functions. The mTOR complex 1 (mTORC1) is defined by the presence of Raptor, mLST8/GβL, Deptor, and PRAS40 [1, 2, 3, 4, 5•, 6, 7], whereas Rictor, GβL, Protor, Deptor, and mSin form mTORC2 [8, 9, 10, 11, 12] (see Figure 1). In addition to their differential sensitivity to rapamycin, mTORC1 and 2 are activated in different ways and have distinct substrate specificity. mTORC1,
Complex loops of regulation — all roads lead to mTOR
mTOR, as a master regulator of a variety of inputs, is subjected to different mechanisms that tightly and coordinately regulate its activation. Many positive and feedback loops have been described lately and most likely other regulatory loops will be deciphered in the near future.
Rapamycin-based therapy
Extensive basic research with rapamycin showed high specificity toward mTORC1 inhibition. This has encouraged a number of clinical trials using this compound as an anticancer drug, but in fact, rapamycin and its first generation analogs temsirolimus and everolimus have proven modest success in clinical trials, reflecting an incomplete understanding of mTOR functions. These small molecules are allosteric inhibitors of mTOR that block S6K1 phosphorylation, but it has become evident that not all
Conclusions
In the last years, substantial progression in the understanding of how mTOR signaling pathway occurs has taught us that there are still significant aspects of mTOR regulation that need further clarification. The mechanism underlying the induction of cell death versus cell-cycle arrest in different cell lines treated with mTOR inhibitors, the existence of additional feedback loops triggered by S6K1 and how these loops affect therapeutic responses should be addressed in the future. Moreover, a
References and recommended reading
Papers of particular interest, published within the period of review, have been highlighted as:
• of special interest
•• of outstanding interest
Acknowledgements
We thank NIH and HHMI for funding our work on mTOR. A.E. is supported by the Human Frontiers Science Program.
References (58)
- et al.
Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action
Cell
(2002) - et al.
mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery
Cell
(2002) - et al.
GbetaL, a positive regulator of the rapamycin-sensitive pathway required for the nutrient-sensitive interaction between raptor and mTOR
Mol Cell
(2003) - et al.
Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control
Mol Cell
(2002) - et al.
DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival
Cell
(2009) - et al.
Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40
Nat Cell Biol
(2007) - et al.
SIN1/MIP1 maintains rictor–mTOR complex integrity and regulates Akt phosphorylation and substrate specificity
Cell
(2006) - et al.
Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive
Nat Cell Biol
(2004) - et al.
Phosphorylation and regulation of Akt/PKB by the rictor–mTOR complex
Science
(2005) - et al.
The TSC1–TSC2 complex is required for proper activation of mTOR complex 2
Mol Cell Biol
(2008)
Characterization of Rictor phosphorylation sites reveals direct regulation of mTOR complex 2 by S6K1
Mol Cell Biol
Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation
Proc Natl Acad Sci U S A
mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1)
Biochem J
PI3K and mTOR inhibitors: a new generation of targeted anticancer agents
Curr Opin Cell Biol
Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers
Nat Med
Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling
Genes Dev
AMPK phosphorylation of raptor mediates a metabolic checkpoint
Mol Cell
A serine/threonine kinase gene defective in Peutz–Jeghers syndrome
Nature
PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase
Mol Cell
mSin1 is necessary for Akt/PKB phosphorylation, and its isoforms define three distinct mTORC2s
Curr Biol
Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton
Curr Biol
Identification of Sin1 as an essential TORC2 component required for complex formation and kinase activity
Genes Dev
Molecular mechanisms of mTOR-mediated translational control
Nat Rev Mol Cell Biol
Regulation of TORC1 by Rag GTPases in nutrient response
Nat Cell Biol
The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1
Science
The TSC1–2 tumor suppressor controls insulin–PI3K signaling via regulation of IRS proteins
J Cell Biol
Role of mTOR in the degradation of IRS-1: regulation of PP2A activity
J Cell Biochem
A rapamycin-sensitive pathway down-regulates insulin signaling via phosphorylation and proteasomal degradation of insulin receptor substrate-1
Mol Endocrinol
Mammalian target of rapamycin pathway regulates insulin signaling via subcellular redistribution of insulin receptor substrate 1 and integrates nutritional signals and metabolic signals of insulin
Mol Cell Biol
Cited by (377)
Raptor levels are critical for β-cell adaptation to a high-fat diet in male mice
2023, Molecular MetabolismDEPTOR loss impairs brown adipocyte development in vitro but has limited impacts in mice
2023, Molecular MetabolismEmerging roles of PHLPP phosphatases in the nervous system
2022, Molecular and Cellular NeuroscienceHyperactivation of mTOR and AKT in a cardiac hypertrophy animal model of Friedreich ataxia
2022, HeliyonCitation Excerpt :Notably, rapamycin treatment did not mitigate the increase in p-S473-Akt levels in some Fxn cKO mice (Figure 6A). Extensive research has shown that a complex branching and looping positive and feedback signaling network modulates the function of mTOR and AKT (Efeyan and Sabatini, 2010; Manning and Toker, 2017). For instance, suppression of mTORC1 activity by rapamycin prevents the degradation of insulin receptor substrate 1 (IRS-1) and augments AKT activation in several cancer cell types, suggesting that the potential anti-hypertrophy activities of rapamycin can be counterbalanced by the release of feedback inhibition of AKT activation (Soares et al., 2013).
Targeting pyruvate kinase M2 signaling for development of effective cancer therapy
2022, Protein Kinase Inhibitors: From Discovery to Therapeutics